Cost‐effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India

Open Access
Publisher Website
Google Scholar
Abstract
Objectives To assess the cost‐effectiveness of current monotherapies and prospective combinations for treating visceral leishmaniasis (VL) in Bihar, India in terms of years of life lost (YLL) averted as well as deaths averted. Methods We employed two methods to estimate the number of avertable deaths in our analysis: one using estimated mortality, the other using direct incidence estimates for VL. Costs of care are based on an average private hospital in Bihar, and data on drug costs were obtained both locally and from the World Health Organization. Results The cost of monotherapies per averted YLL ranged from US$2 for paromomycin in an outpatient setting to US$20–22 for AmBisome® at 20 mg/kg. The corresponding costs per death averted ranged from US$53–54 to US$523–527. Combinations ranged US$5–8 per YLL averted and US$124–213 per death averted. Conclusion The available treatments for VL are cost‐effective, and our mortality and incidence‐based methods produce consistent estimates. The combinations considered here were more cost‐effective than most monotherapies. Having multiple treatment options and combining drugs are also likely to reduce drug pressure and prolong the drugs’ life‐span of effective use.